



Samyang Biopharmaceuticals Corporation

www.samyangbiopharm.com/eng

Samyang Biopharm is specialized in development of small-molecule drugs, new biologic drugs and virus vaccines and commercialization of DDS-based modified drugs and first generics for cancer treatment. Samyang Biopharm is exporting its oncology products and expands its product portfolio. Samyang's cytotoxic facility obtained GMP certifications from KR, EU, and JP. the new facility is expected to achieve full cGMP operation. Samyang Biopharm USA Inc. in Cambridge concentrates on global new drug development in immune-oncology and rare diseases.

Main Products

FDI	Product	Formulation	Strength	Specifications
Polymeric Micelle	Genoxel [®] PM	Lyophilized Injection	30mg, 100mg/vial	In-house
	Nanoxel [®] M	Lyophilized Injection	20mg, 80mg/vial	In-house
Generics for Solid Tumors	Paclitaxel	Liquid Injection	30mg, 100mg, 150mg, 300mg/vial	USP, EP
	Docetaxel	Liquid Injection	20mg, 80mg, 140mg, 160mg/vial	EP
	Oxaliplatin	Liquid Injection	50mg, 100mg, 200mg/vial	EP, JP
	Gemcitabine	Liquid Injection	200mg, 1g/vial	USP
	Pemetrexed	Liquid Injection	1g/vial	In-house
		Liquid Injection	100mg, 500mg/vial	In-house
		Lyophilized Injection	100mg, 500mg/vial	In-house
Generics for Blood Cancers	Everolimus	Oral Tablet	2.5mg, 5mg, 10mg/pk	In-house
	Azacididine	Lyophilized Injection	100mg, 150mg/vial	In-house
	Decitabine	Liquid Injection	40mg, 50mg/vial	In-house
	Bortezomib	Lyophilized Injection	2.5mg, 3.5mg/vial	In-house
	Bendamustine	Liquid Injection	25mg, 100mg/vial	USP
Generis for Supportive Care	Lenalidomide	Oral Tablet	2.5mg, 5mg, 10mg, 15mg, 20mg, 25mg/pk	KP
	Palonosetron	Liquid Injection	0.075mg, 0.25mg, 0.4mg/vial	KP
	Zoledronic Acid	Liquid Injection	4mg/vial	KP
Transdermal Drug Delivery System	Diclofenac	Plaster	120mg	BP
		Patch	14mg, 28mg, 42mg	EP
	Nicotine	Gum	2mg	USP
		Patch	12µg/h, 25µg/h, 50µg/h, 100µg/h	EP
	Rivastigmine	Patch	6mg(4.6mg/24hr), 12mg(9.5mg/24hr)	EP
	Tulobuterol	Patch	0.5mg, 1mg, 2mg	In-house
	Nitroglycerin	Patch	22.4mg(0.2mg/hr)	USP

API	Product	Package	DMF
Cytotoxic APIs	Paclitaxel	Up to 500 g	US DMF, CEP, KDMF
	Docetaxel	Up to 500 g	US DMF, CEP
	Pemetrexed	Up to 500 g	KDMF
	Bortezomib	Up to 500 g	KDMF
	Cabazitaxel	Up to 500 g	-

R&D Pipeline

Country	Technology	Research	Clinical	Registration	
Korea	PM	Paclitaxel	████████████████████	████████████████████	████████████████████
		Docetaxel	████████████████████	████████████████████	████████████████████
		SYP-1261	████████████████████	████████████████████	████████████████████
	PNP	SYP-0709	████████████████████	████████████████████	████████████████████
		SYP-0709S	████████████████████	████████████████████	████████████████████
	SEMP	SYO-1906	████████████████████	████████████████████	████████████████████
	FDT	Ramosetron	████████████████████	████████████████████	████████████████████
	CSDS	Prednisolone	████████████████████	████████████████████	████████████████████
	SENS	SYP-1758	████████████████████	████████████████████	████████████████████
		SYP-1765	████████████████████	████████████████████	████████████████████
SYP-1914		████████████████████	████████████████████	████████████████████	
Metabolic Anticancer	SYO-2001	████████████████████	████████████████████	████████████████████	
USA	Monoclonal antibody	SYB-010	████████████████████	████████████████████	
		SYB-020	████████████████████	████████████████████	

CEO
Taeung Eom

Location
6th Floor, 295 Pangyo-ro,
Bundang-gu, Seongnam-si,
Gyeonggi-do, South Korea

- Specialty
1. Drug delivery system of anti-cancer drugs based on small molecules, virus and nucleic acid
 2. New biologic anticancer drugs and Rare disease drugs
 3. Cytotoxic anticancer drugs

Tel / Fax / E-mail
T. 82-2-2157-9111
F. 82-2-2157-9062